A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).
Janin ChandraW P WooN FinlaysonHoward Yu-Hao LiuM McGrathRahul M LadwaM BrauerY XuS HansonBenedict J PanizzaIan Hector FrazerSandro V PorcedduPublished in: Cancer immunology, immunotherapy : CII (2020)
AMV002 was well tolerated at all dose levels and resulted in enhanced specific immunity to virus-derived tumour-associated antigens in subjects previously treated for HPV-associated OPSCC.